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INTRODUCTION
The enzyme catechol O-methyltransferase (COMT; EC 2.1.1.6) inactivates substrates containing a catechol structure by methylating one of the phenolic hydroxy groups in mammals [1] . These substrates include catechol hormones and neurotransmitters, such as dopamine and adrenaline [2] .
All mammalian tissues studied contain two forms of the COMT protein. Most of the activity is due to the cytoplasmic form of the enzyme (S-COMT), whereas the membrane-bound form (MB-COMT) is responsible for a smaller proportion [3] [4] [5] [6] . Both protein forms have been characterized from rat and man. The molecular mass of S-COMT is 24 kDa in rat [7] and 25 kDa in man [8] , and that of the larger form, MB-COMT, is 28 kDa [6] and 30 kDa [6, 9] in rat and man respectively. Although S-and MB-COMT have similar biochemical properties, MB-COMT differs structurally from S-COMT by having a hydrophobic extension (43 amino acids in rat and 50 amino acids in man) at the N-terminus. This region contains a signal-anchor peptide directing and anchoring the MB-COMT polypeptide to cell membranes [10] .
COMT cDNAs have been cloned from rat liver [11] , porcine liver [9] , human placenta [12] and one human cell line [9] . Results from these studies strongly suggest the presence of only one gene for COMT in rat and man. The structure of the rat COMT gene has been characterized [13] . It contains an S-ATG codon in the second exon and an MB-ATG codon 129 bp upstream for the translation initiation of S-COMT and MB-COMT polypeptides respectively. The coding sequence for 221 amino acids downstream of the S-ATG codon is identical for both enzyme forms, and the region between the ATG initiation codons encodes the signal-anchor peptide. This organization enables the production of two COMT forms from one gene. The gene is regulated by two promoters, P1 and P2, P1 expressing a 1.6 kb transcript (SmRNA) containing only the S-AUG translation initiation codon of S-COMT. The P2 promoter expresses 1.9 kb transcripts (MBmRNA) containing both AUG initiation codons and having a coding capacity for both enzyme forms.
According to our previous work [13] and the present report, only the 1.9 kb MB-mRNA species can be detected in rat brain. However, both COMT proteins can be found in the brain [3, 4, 6] . We have proposed that the leaky scanning mechanism of translation initiation [14, 15] is responsible for the production of S-and MB-COMT forms from this single mRNA species in the rat brain and other tissues [10, 13] . Also, the involvement of proteolytic processing has been suggested [16] .
We report here that, in rat, the bifunctional 1.9 kb MBmRNA is able to produce both S-and MB-COMT forms by using alternative AUG initiation codons. Analyses of 5'-endspecific cDNA clones show that the 1.9 kb MB-mRNA class consists of alternatively spliced species in which the effectiveness of the MB-AUG codon in initiating translation is different. We also provide evidence suggesting that, under the experimental conditions used, no proteolytic cleavage of the MB-COMT to the S-COMT form occurs.
MATERIALS AND METHODS Western-blot analysis
Selected rat tissues were disrupted in PBS, and 25-50 ,ug of total proteins subjected to SDS/PAGE (10 % gels). Western blotting was performed as described previously [7] using polyclonal antiserum raised against the recombinant S-COMT polypeptide.
Northern-blot analysis Total RNA was extracted from different rat tissues and analysed by Northern blotting as described previously [13] . The probe Abbreviations used: COMT, catechol 0-methyltransferase; S-COMT, MB-COMT, soluble and membrane-bound forms of COMT.
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All nucleotide sequences described here will appear in the EMBL/GenBank/DDBJ Nucleotide Sequence Databases under the accession numbers Z12651 and Z12652. ;# **_* t t i Figure 1 Characterization of COMT proteins and transcripts in rat tssues (a) Western-blot analyses of rat tissues. After disruption of the tissues in PBS, proteins were subjected to SDS/PAGE (10% gels), and Western blotting was carried out as described [7] using polyclonal anti-COMT serum. COMT polypeptides were detected by using a second antibody conjugated with horseradish peroxidase. 
Nuclease protection
To reveal the 5' ends of COMT transcripts near the S-AUG codon in the rat liver and telencephalon poly(A)+ RNAs, RNAase-protection assays were carried out. The RNA probes used were NP2-and NP3-containing nucleotides from -630 to + 183 and from -413 to + 183 respectively of the rat genomic COMT sequence [13] .
Ampiffication of the 5' end of the COMT mRNA
The amplification of the 5' end of the rat heart COMT cDNA has been described previously [13] . The COMT-specific primers PR3 and PR4 downstream of the MB-ATG codon were used in the cDNA synthesis and PCR reactions respectively (see Table 1 and Figure 3a ). The clones derived from the tailing reactions were screened with a 39 bp 32P-labelled COMT-specific fragment (positions + 1 to + 39; Figure 3a ). A total of 40 COMT-specific clones were characterized by sequencing.
Construction of the full-length cDNA clones
The 5'-end-specific cDNA fragments derived from the tailing reactions were amplified as follows. The fragments without or with a 27 bp region which is located upstream of the MB-ATG codon were used as templates. The downstream primer was PR4 ( Figure 3 and Table 1 ) in exon 2 of the COMT gene. The upstream primer, containing a Sacl site in the 5' end, was PR5 in the non-coding exon 1. The resulting PCR fragments were then used as megaprimers [17] to amplify a fragment from a rat genomic DNA clone. In these cases, the downstream primer was PR6 within the S-COMT coding region. This primer contains an internal BstXI site. The SacI-BstXI fragments of the PCR products were joined to the BstXI-HindIII fragment of the rat liver COMT cDNA clone [11] . The resulting Sacl-HindIll inserts containing the whole coding region of the rat COMT gene and the 5' end non-coding regions without (clone 1) or with (clone 2) a 27 bp sequence were ligated into the Sacl-HindIll sites of the vector pGEM3 (Promega) (Figure 3b ). For the experiments in COS-7 cells, the Sacl-HindIll fragments were blunted and ligated into the blunted KpnI site downstream of the transcription initiation site of the pSVL SV40 expression vector (Pharmacia) in an appropriate orientation.
Plasmid construction for the study of the translation initiation contexts The construction of clones 3, 4 and 5 ( Figure 3b ) has been described previously under the names pR-MB2, pR-S1 and pR-MB3 respectively [10] . Point mutations around the MB-ATG codon in clone 6 ( Figure  3b ) were created by using PCR as follows. The upstream primer was PR7 ( Figure 3a , Table 1 The COMT-specific fragment of clones 3, 4 and 5 (BamHIHindlIl in clones 3 and 5, and HindIlI in clone 4) was blunted and ligated into the blunted KpnI site of the vector pSVL SV40 to carry out the experiments in COS-7 cells.
In vitro and in vivo experiments
In vitro translations of the COMT plasmid constructs were performed with the TNT T7 Coupled Reticulocyte Lysate System (Promega) according to the manufacturer's recommendations. In some experiments, canine pancreatic microsomal membranes (Promega) were added (4 eq./reaction). For pulse-chase experiments the lysates were incubated in the presence of In vivo translations were performed using COS-7 cells (African Green monkey kidney cells, ATCC CRL-165 1). Cells were cultured as described [18] and transfected with 5,tg of DNA constructs using the lipofectin procedure [19] . After 18 h incubation, cells were labelled with [35S]methionine (40 ,tCi/ml) in methionine-free medium for the time period indicated. The chase was performed by incubation with 1 mM (final concentration) non-radioactive methionine for the time period indicated. Rat glial tumour C6 cells (ATCC CCL 107) were labelled with [35S]methionine (200 ,uCi/ml) for 13 h in methionine-free minimal essential medium (Gibco). The chase with 1 mM (final concentration) non-radioactive methionine was performed for the time period indicated. Cells were lysed and equal amounts of proteins were incubated with 1: 100 dilution of the polyclonal anti-COMT serum, and precipitated with Protein A-Sepharose (Pharmacia) as described [18] .
In vitro and in vivo samples were subjected to SDS/PAGE (10 % gels), dried and exposed to Kodak X-Omat films. Quantification of the autoradiograms and Western-blot filters was carried out by densitometry (Ultroscan XL; LKB). The rest of the COMT sequence is as described previously [13] .
RESULTS

Different COMT polypeptides and mRNA size classes in rat tissues
To observe the presence of the COMT polypeptides in selected rat tissues, Western blotting was performed using a polyclonal anti-COMT serum recognizing both COMT forms [6] . A 24 kDa S-COMT and 28 kDa MB-COMT were detected in liver (93 % of COMT proteins were in the S-COMT form), kidney (75 %), heart (79 %), cerebellum (86 %) and telencephalon (69 %) (Figure la) . The liver contained high amounts of COMT protein [20] [21] [22] , confirming previous results. Northern-blot analysis (Figure lb) indicates the presence of the two classes of COMT-specific transcripts, with sizes of 1.6 kb (S-mRNA) and 1.9 kb (MB-mRNA). In the liver and kidney most of the mRNA is the shorter species, whereas in the heart and brain tissues the longer mRNA is dominant. PCR was used to confirm the presence of the 1.9 kb mRNA in the liver and kidney. Amplification with primers PRI and PR2 should give a 637 bp fragment if the 1.9 kb mRNA species is present. As shown in Figure l(c) , this is the case in all the tissues studied.
The 5' ends of rat 1.6 kb COMT S-mRNA have, been shown to reside 17-18 nt upstream of the S-AUG codon [13] . This region also contains putative splicing acceptor sites enabling the formation of longer splicing variants which would have only the S-AUG codon. To detect such mRNAs in rat telencephalon and liver (as a control) poly(A)+ RNAs, they were analysed by the nuclease-protection method using probes NP2 and NP3 [13] . Both of these probes should give a pattern of 70-75 bp-protected fragments if the tissue contains the 1.6 kb S-mRNA and/or putative long splicing forms. The results ( Figure Id) confirm that the liver contains the 1.6 kb S-mRNA in large amounts, and that the S-mRNA and hypothetical long splicing forms containing only the S-AUG codon are either absent from the telencephalon or the quantity is below the detection limit of this sensitive method. Using the same technique, it has been shown previously that the rat heart tissue contains a small amount of 1.6 kb SmRNA [13] . Thus it can be concluded that the 1.9 kb MBmRNA is constitutively expressed in different rat tissues at variable levels, whereas the production of the shorter 1.6 kb SmRNA is tissue-specifically regulated.
MB-mRNAs consist of different splicing variants
The transcriptional initiation and overall splicing pattern of the longer 1.9 kb rat COMT mRNA has been characterized earlier [13] . In order to disclose structural variation in the 5' non-coding region of the 1.9 kb mRNA in detail, rat heart poly(A)+ RNA was used to prepare cDNA clones because of its high content of 1.9 kb MB-mRNA. A total of 40 separate 5'-specific COMT cDNA clones were isolated. Sequencing of the clones revealed two different splicing variants (Figure 2) . One of the forms (MBmRNA 1) was identical with that described previously [13] , where the splicing of the non-coding exon 1 occurs in the splicing acceptor site located immediately upstream of the MB-AUG codon. In the other form (MB-mRNA 2) the splicing occurs in the acceptor site located 27 nt upstream.
The ratios of the two MB-mRNA splicing variants in selected rat tissues were determined using the solid-phase minisequencing technique [23] . The analysis of several different purified rat RNA preparations was performed with primers distinguishing between the two variants. The results indicated that the MB-mRNA 1 form was dominant in all tissues studied (liver, kidney, heart, stomach, duodenum, telencephalon, cerebellum, pons medulla of MB-mRNA without (clone 1) or with (clone 2) the 27 bp fragment were prepared (Figure 3b ). The 5' end of both cDNAs is located 160 bp upstream of the MB-ATG codon. This region has previously been determined to contain the major transcription initiation sites of the 1.9 kb transcripts [13] . The translational capacities of the constructs were analysed in transfected monkey COS-7 cells. The results of the immunoprecipitations (Figure 4) show that the efficiency of translation initiation from the MB-AUG codon in these cells is different in the two MB-mRNA splicing variants. In clone 1 (no 27 nt sequence, G at -3), the ratio of the MB-to S-COMT form produced was 0.7 (lane 3) and in clone 2 (27 nt sequence present, C at -3) it was 0.3 (lane 4).
To determine whether the observed differences in the translation initiation was in fact due to the change of the nucleotide at position -3 or the RNA sequence(s) located further upstream of this site, the following two constructs were analysed in COS-7 cells. In clone 3 (Figure 3b ) the COMT-specific sequence starts at position -3 (C at this site). Clone 5 contains a point mutation at position -3 (changing C to A) altering the initiation context of MB-AUG to be more favourable [14, 24] . The in vivo results (Figure 4) show that the optimizing of the MB-AUG codon context indeed enhances the translation initiation from this codon. The ratio of MB-to S-COMT polypeptide produced is higher (0.2 in clone 3 and 0.6 in clone 5) when MB-AUG is in the more favourable context (Figure 4 , lanes 5 and 6 respectively). The ratios of COMT polypeptides produced from these constructs were comparable with those produced from the fulllength clones 1 and 2. This suggests that the differences in the efficiency of translation initiation from MB-AUG in the splicing variants is mainly due to the nucleotide change at position -3.
It can also be seen that clone 4 (no MB-ATG codon) produced only S-COMT protein as expected (Figure 4, lane 7) . and striatum). The amount of MB-mRNA 2 was always 70 or less of total MB-mRNA.
Effect of the 27 nt sequence and context changes on the translation initiation in the MB-AUG codon The presence of the 27 nt sequence alters the translation initiation context of the MB-AUG by changing the G at position -3 to C.
To analyse whether this alteration affects the initiation of translation from this AUG codon, full-length cDNA constructs Determination of the proteolytic processing of MB-COMT polypeptide To determine if proteolytic cleavage participates in the production of the S-COMT form from MB-COMT, the following pulse-chase experiments were carried out in vitro. Clones 1 and 2 ( Figure 3b) were translated in rabbit reticulocyte lysates supplemented with canine microsomal membranes. Densitometric scanning showed that the ratio of MB-to S-COMT polypeptide remained unchanged in both clones (3.1 and 1.7 in clone 1 and 2 respectively), indicating that no proteolytic processing of MB-COMT to S-COMT occurred ( Figure 5 , lanes 1-6). To investigate whether rapid proteolytic processing after the synthesis of MB-COMT would give rise to S-COMT protein, a pulse-chase experiment was performed in vitro using an 8 min pulse and a 60 min chase. Clone 6 (Figure 3b ), which contains mutations at positions -3 (changing C to A) and + 4 (changing C to G), was used in this experiment. Because of the optimal context of the MB-AUG in clone 6, the predominant translation product would be MB-COMT, thus making the detection of the appearance of the S-COMT protein easier. The results ( Figure 5 , lanes 7-10) show no difference in the relative amount of S-COMT produced during the pulse or after the chase. A similar result was obtained when canine microsomal membranes were present in the lysate.
To analyse if proteolytic processing occurs in vivo, a pulsechase experiment was performed in COS-7 cells transfected with clone 3 using a labelling time of 30 min followed by 3 h chase. The results show no conversion of MB-COMT into S-COMT ( Figure 5, lanes 11 and 12) . Furthermore, the in vivo pulse-chase studies were performed with rat glial tumour C6 cells expressing only the 1.9 kb MB-mRNA (data not shown) analogously to the rat brain tissues. Cells were labelled for 13 h and then chased for 2, 5 and 8 days. The MB/S ratios varied between 1.1 and 1.4 ( Figure 5, lanes 13-16) .
Together, the in vitro and in vivo experiments suggest that proteolytic processing does not significantly contribute to the production of S-COMT protein. Rather, it is expressed from the 1.9 kb MB-mRNAs by the leaky scanning mechanism of translation initiation or from the 1.6 kb S-mRNA. This is supported by the fact that the translation initiation context of MB-AUG in rat is not optimal (C at + 4) and thus the codon is able to leak during translation.
DISCUSSION
COMT enzyme occurs in mammalian cells in two forms (soluble and membrane-bound) having different subcellular localizations [3, 20, 22] . To understand how the two forms of this enzyme are synthesized in rat tissues, we have previously shown that two promoters in the single COMT gene regulate the expression of separate MB-and S-mRNAs [13] . This and our earlier study [13] show that some rat tissues, such as the liver and kidney, contain both COMT mRNA species, whereas some of the tissues, such as the brain, contain only MB-mRNA. Despite this clearcut difference in the COMT mRNA composition between the tissues, the majority of COMT protein in them consists of S-COMT (see Figure la) . Protein analyses revealed S-COMT as a duplet band in some of the rat tissues studied (liver, telencephalon, cerebellum). Notably, this phenomenon is not observed in the continuous C6 cell line, where only the smaller S-COMT species is detected (results not shown). The reason for the different S-COMT species in different tissues is not clear at present. Here we exclude the possibility that the 1.9 kb mRNA in rat brain contains a hypothetical splicing variant which lacks the MB-AUG, and thus could be responsible for the synthesis of S-COMT polypeptide. Consequently, the MB-mRNA must direct the production of both COMT proteins in tissues such as the brain.
Two mechanisms have been proposed to explain the synthesis of the two COMT polypeptides from one MB-mRNA species: (1) the S-COMT form is initiated from the downstream (S-AUG) start codon in the 1.9 kb MB-mRNA by the leaky scanning mechanism of translation initiation [10, 13] , or (2) S-COMT polypeptide is produced by post-translational proteolytic processing from the MB form [9, 16] .
The analysis of COMT MB-mRNA 5'-specific cDNA clones revealed two different mRNA species formed by alternative splicing, MB-mRNA 1 and MB-mRNA 2. Both splicing variants carry MB-and S-AUG codons, but MB-mRNA 2 contains an additional 27 nt sequence upstream of the MB-AUG codon. Notably, this extra sequence alters the translation initiation context of the MB-AUG codon present in MB-mRNA 1 by changing G at position -3 to C in MB-mRNA 2. At position + 4 there is C in both variants. The leaky scanning mechanism of translational initiation states that the nucleotide at position -3 is the most critical one for the efficiency of translation initiation [14] . When there is a purine at this position, the rest of the context has only a marginal effect. If it is not a purine, then the nucleotide at +4 should be G for efficient translation. Also other sequence(s) 5 ' to the start codon and secondary structure can affect the efficiency of translation initiation from a particular AUG [15] .
The efficiency of translation initiation in MB-mRNA 1 and 2, and the effect of upstream non-coding region(s), were analysed in monkey COS-7 cells. The results indicated that the alteration in MB-to S-COMT ratio was due to the change of the nucleotide at position -3, and not due to the sequence(s) further upstream in mRNAs possibly affecting the translation initiation, for example via a secondary structure. A minor fraction of 1.9 kb mRNA was found to initiate transcription at the P2 promoter approximately 50 nt further upstream [13] bringing a GC-rich region to the 5' end of the splicing variants. This GC-rich (and hence putatively highly structured) sequence did not affect the ratio of MB-and S-COMT produced (results not shown). Even though alternative splicing in 5' non-coding regions is not uncommon [25] , to our knowledge this is the first case where splicing changes the context and thus the efficiency of the translation initiation from a particular AUG start codon.
MB-mRNA 1 and 2 are formed by choosing between two alternative 3' splicing acceptor sites which are used at different efficiencies. It is known that elements necessary, but not sufficient, for efficient 3' splicing include a 3' acceptor site and a polypyrimidine tract [26] . The downstream 3' splice site used by MBmRNA 1 is preceded by a pyrimidine-rich sequence, whereas the region preceding the splice site of MB-mRNA 2 is pyrimidinepoor. The determination of the tissue-specific distribution of 1.9 kb MB-mRNA splicing variants, by applying the solid-phase minisequencing method [23] , showed that all tissues studied contained 7 % or less of MB-mRNA 2. It remains to be shown whether selection of the splicing acceptor site in the MB-mRNA is used to regulate the balance between S-and MB-COMT proteins, for example in other tissues or during ontogeny.
The putative post-translational proteolysis of MB-COMT to yield S-COMT was studied by expressing constructs that produce different ratios of the two COMT proteins by in vitro translation and in transfected COS-7 cells. These experiments indicated no production of S-COMT from MB-COMT. Furthermore, in pulse-chase studies with the rat glioma C6 cell line using chase periods of up to 8 days, the ratios of COMT products stayed at similar levels. This suggested that no slow proteolytic cleavage of MB-COMT to S-COMT occurred and that the half-lives of the S-and MB-COMT forms were similar in vivo. Proteolysis was also studied by incubating in vitro translation products of clone 3 in the presence of different amounts of rat brain and liver crude tissue homogenates for 18 h at 37 'C. No change in the total amounts of MB-and S-COMT or in the MB/S ratios was observed between the samples or compared with the control incubated without the homogenates (results not shown).
Together the in vitro and in vivo results suggest that S-COMT is not a cleavage product of the MB-COMT form. Rather, depending on the COMT mRNA composition in a particular tissue, S-COMT is produced by either alternative use of translation initiation codons in MB-mRNAs or translation from SmRNA, or both. This is further supported by the fact that the MB/S ratios in COS-7 cells transfected with clone 1, and C6 cells and telencephalon tissue containing only the 1.9 kb transcripts, are at comparable levels.
Protein analyses of rat crude tissue homogenates with specific antisera revealed that the relative amount of the MB-COMT form in the rat tissues studied is higher than reported previously based on activity measurements [27] . Recent studies have suggested that the MB-COMT polypeptide is located in the rough endoplasmic reticulum (J. Peranen, T. Karhunen, C. Tilgmann, P. Panula and I. Ulmanen, unpublished work). The fractionation procedures used in the earlier quantifications of COMT proteins may have underestimated the amount of the MB-COMT form.
